Jim Cramer on Eli Lilly: “Brilliant Management”

Eli Lilly and Company (NYSE:LLY) was among the stocks Jim Cramer discussed on Mad Money, highlighting several companies with market caps over a trillion dollars. Cramer highlighted the company’s new cholesterol drug’s Phase 3 trial, as he commented:

Finally, the 11th largest US company, holy cow…. smaller than Micron but still just over 1 trillion, Eli Lilly, the drug maker that’s seen huge growth in scale in recent years because of the strength of the GLP-1 drugs for diabetes and weight loss. But as good as it’s been, the Lilly story somehow continues to improve. Last week, we learned that it’s got this new weight loss drug, it’s called Retatrutide, which was very effective in Phase 3 trials. Seems to be able to bust fat, not muscle, although that’s not what the company is hailing or claiming. And over the weekend, a separate gene therapy treatment showed great data when it comes to reducing cholesterol. Now, there’s a reason this is the only healthcare company to earn a trillion-dollar valuation, brilliant management.

Photo by Joshua Mayo on Unsplash

Eli Lilly and Company (NYSE:LLY) develops and markets medicines for diabetes, obesity, oncology, immunology, neuroscience, and other chronic conditions.

While we acknowledge the risk and potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LLY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1